When I Try to Imagine the Best Investment Opportunity for the Next 10 Years, Costco Stock Just Doesn't Make the Cut. That's Why I Keep Coming Back to This Stock.

The article argues Costco (COST) is a great business but the stock looks expensive, citing a 0.6% dividend yield and valuation multiples (P/S 1.4x vs 1.2x average; P/E 47x vs ~45x; P/B 12.6x). In contrast, it frames McCormick (MKC) as undervalued with a historically high ~3.6% yield and cheaper-than-average multiples (P/S ~2x vs 3x, P/E ~9x vs 25x, P/B ~2x vs 3.8x) despite near-term earnings pressure from inflation. The key catalyst is McCormick’s planned acquisition of Unilever’s food business, described as a larger deal that could require added leverage, creating execution risk alongside expected upside.

Analysis

The real signal is not “COST expensive” so much as “quality duration is being repriced.” COST can keep comping at a premium as long as traffic and membership renewals stay pristine, but at ~high-40s earnings the stock needs near-perfect execution; any softening in basket growth or a margin giveback would compress the multiple fast. That makes it a slower, more rate-sensitive compounder than the market often assumes, with upside increasingly dependent on no-miss execution rather than operating acceleration.

MKC is the more interesting setup because the market is discounting the balance-sheet step-up and underwriting only the near-term leverage drag, not the medium-term synergy math. If the UL food assets are integrated cleanly, MKC gets a wider brand footprint and more pricing leverage with retailers, while the biggest losers are smaller flavor/condiment suppliers that lack scale to absorb input inflation or defend shelf space. The key second-order effect is that the deal can shift MKC from a simple defensive staple into a slightly more levered, more diversified branded-food platform that may deserve a higher terminal multiple once debt stabilizes.

The consensus miss is that “cheap” staples often stay cheap unless there is a visible catalyst; here, the catalyst is not growth but normalization. If inflation moderates and acquisition financing lands without a balance-sheet shock, MKC has asymmetric rerating potential over 6-18 months, whereas COST’s premium is already paying for resilience. The main falsifier for MKC is slower-than-expected margin recovery or a higher-for-longer rate environment that keeps leverage expensive; for COST, it’s a comp miss or membership churn signal that breaks the premium multiple within 1-2 quarters.

Key Decisions for Investors

• Initiate a modest long MKC / short COST pair on a 6-12 month horizon: long the valuation reset and post-deal synergy optionality, short the crowded premium multiple. Use small sizing because both are defensive and the pair is more about relative re-rating than absolute alpha.
• Buy MKC on pullbacks after financing terms and integration guidance are confirmed; target a 12-month thesis on leverage normalization and synergy delivery. Risk/reward improves if the stock stays below historical P/E/P/S bands while the deal closes cleanly.
• Avoid shorting COST outright unless there is a clear catalyst for comp deceleration or renewal weakness; the better expression is a relative short vs. lower-multiple defensives or vs. MKC. The stock can remain expensive longer than valuation-based bears expect.
• Watch UL as a potential balance-sheet beneficiary if divestiture proceeds support de-levering and portfolio simplification; this is more of a capital-allocation tailwind than an operating breakout, so any trade should wait for use-of-proceeds clarity.
• Set alerts for MKC on acquisition financing spreads and interest expense guidance; if debt cost or integration commentary deteriorates, the long thesis weakens quickly and should be cut.